Provided by Tiger Trade Technology Pte. Ltd.

ABBISKO-B

13.540
-0.010-0.07%
Volume:1.25M
Turnover:16.80M
Market Cap:9.13B
PE:133.52
High:13.600
Open:13.550
Low:13.150
Close:13.550
52wk High:19.780
52wk Low:6.560
Shares:674.00M
HK Float Shares:674.00M
Volume Ratio:1.07
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.101
ROE:2.85%
ROA:0.78%
PB:4.14
PE(LYR):133.52
PS:13.00

Loading ...

Abbisko Therapeutics’ Csf-1R Inhibitor Pimicotinib Approved by the China Nmpa, Addressing the Treatment Gap for Tenosynovial Giant Cell Tumor

THOMSON REUTERS
·
Dec 22, 2025

Abbisko Unit Gets China Nod for Tenosynovial Giant Cell Tumor

MT Newswires Live
·
Dec 22, 2025

BRIEF-Abbisko Cayman Says Abbisko Therapeutics' CSF-1R Inhibitor Pimicotinib Approved By China NMPA

Reuters
·
Dec 22, 2025

ABBISKO-B (02256): ABBISK Medicine's CSF-1R Inhibitor Beijiemai® Approved by China's NMPA

Stock News
·
Dec 22, 2025

Abbisko Therapeutics Wins China NMPA Approval for Pimicotinib

Reuters
·
Dec 22, 2025

Abbisko Cayman Ltd - Abbisko Therapeutics' Csf-1R Inhibitor Pimicotinib Approved by the China Nmpa

THOMSON REUTERS
·
Dec 22, 2025

Both retail investors who control a good portion of Abbisko Cayman Limited (HKG:2256) along with institutions must be dismayed after last week's 5.9% decrease

Simply Wall St.
·
Dec 21, 2025

Abbisko Unit Begins Phase 2 Dosing of ABSK061 for Achondroplasia

MT Newswires Live
·
Dec 16, 2025

ABBISKO-B (02256): First Patient Dosed in Phase II Clinical Trial of FGFR2/3 Inhibitor ABSK061 for Achondroplasia Treatment

Stock News
·
Dec 16, 2025

Abbisko Therapeutics Doses First Patient in Phase II Trial of ABSK061 for Achondroplasia

Reuters
·
Dec 16, 2025

ABBISKO-B (02256): Abbisko Announces Phase II Clinical Preliminary Results of Oral PD-L1 Inhibitor ABSK043 Combined with EGFR Inhibitor Furmonertinib for NSCLC at ESMO Asia 2025

Stock News
·
Dec 08, 2025

Abbisko Cayman Reports Positive Phase II Results for Oral PD-L1 Inhibitor ABSK043 in NSCLC Combination Therapy

Reuters
·
Dec 08, 2025

10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled

Stock News
·
Dec 03, 2025

Abbisko Cayman (02256) Releases Monthly Return for November 2025

Bulletin Express
·
Dec 03, 2025

Abbisko's IND Application for Cancer Therapy Cleared by U.S. FDA

MT Newswires Live
·
Dec 02, 2025

BRIEF-Abbisko Cayman Says U.S. FDA Clears IND Application For ABSK141

Reuters
·
Dec 01, 2025

ABBISKO-B (02256): FDA Approves IND Application for Oral Small Molecule KRAS G12D Inhibitor ABSK141

Stock News
·
Dec 01, 2025

Abbisko Cayman - U.S. FDA Clears Ind Application for Abbisko's Absk141

THOMSON REUTERS
·
Dec 01, 2025

Abbisko Therapeutics Wins FDA IND Clearance for KRAS G12D Inhibitor

Reuters
·
Dec 01, 2025

Is Abbisko Cayman Limited (HKG:2256) Trading At A 39% Discount?

Simply Wall St.
·
Nov 30, 2025